ALXO

1.0502.94%
RH

Rekha Hemrajani

Independent Non-Executive Director

Ms. Rekha Hemrajani, M.B.A., has been Independent Director at BioAge Labs, Inc. since August 2021. She serves as Independent Non-Executive Director at MaxCyte, Inc. since June 15, 2021. Ms. Hemrajani had been the Chief Executive Officer of Jiya Acquisition Corp. since August 2020 and was its Director since August 2020 until November 2022. She is Independent Director of LB Pharmaceuticals Inc from September 10, 2025. Ms. Hemrajani has been an Independent Non-Executive Director of ALX Oncology Holdings Inc. since April 2020. Ms. Hemrajani served as a Director of Adverum Biotechnologies, Inc. from May 1, 2019 to May 2021. Ms. Hemrajani served as the President, Chief Executive Officer and Director at Aravive, Inc. from January 9, 2020 to April 09, 2020. Ms. Hemrajani had been Chief Financial and Operating Officer at Arcus Biosciences, Inc. from March 25, 2019 to September 2019. Ms. Hemrajani was Chief Financial Officer and Senior Vice President of Business & Financial Operations at 3-V Biosciences, Inc. (now Sagimet Biosciences) since February 19, 2015 until 2016. She served as Chief Operating Officer at RAPT Therapeutics, Inc. (formerly known as FLX Bio) from March 2016 to March 19, 2019. Ms. Hemrajani served as Vice President, Head of Licensing and Mergers & Acquisitions Group at Onyx Pharmaceuticals (acquired by Amgen) from 2012 to 2013. Ms. Hemrajani is an experienced strategic leader helping biotech companies with corporate strategy and corporate finance, as well as building product pipelines through corporate development. She has extensive senior management experience within public and private biopharmaceutical companies and bulge bracket investment banks. She was responsible for corporate development strategy, search and evaluation, financial forecasting and analysis, competitive intelligence and transaction execution. Ms. Hemrajani is a senior executive with biopharmaceutical industry experience and has extensive expertise in all aspects of corporate strategy, corporate and business development, financing and strategic planning. From November 2013 to January 2015, Ms. Hemrajani advised privately held companies on strategic corporate development and financing activities at Ravinia Consulting, a consulting firm she founded. She served as Vice President of Business Development at Exelixis from 2003 to 2011. Before Exelixis, she spent in investment banking at Credit Suisse First Boston and Lehman Brothers helping large, small and mid-sized companies in the biopharmaceutical and healthcare industries raise capital in the public and private markets, as well as with mergers and acquisitions. She serves as Director at Ravinia Consulting Inc, Hemmo Pharma LLP and Hemmo Pharmaceuticals Private Limited. She also serves as a Member of the Investment Advisory Board of the Monroe Brown Seed Fund at the University of Michigan. Ms. Hemrajani received her MBA Finance and Marketing from the Kellogg Graduate School of Management, Northwestern University and holds a B.S. in Economics and Computer Science from the University of Michigan.

Positions